Saturday, November 18, 2017
  • 1
  • 2
  • 3
  • 4

Company History

  • Rameda began operations in 1994, and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region
  • The owners commissioned V-Konsult, a leading German design consultant, to create a state-of-the art facility
  • The British Carter Construction company was mandated to complete all the electromechanical works of Rameda’s facilities

  • In 1999, Rameda entered into an agreement with Alcon, the world's second largest manufacturer of consumer vision care products, to manufacture–under license–their ophthalmology products.
  • In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda

  • In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda with the objective of establishing Rameda into a leading player in the pharmaceutical industry.
  • Compass capital placed an aggressive road map for the transformation of the company.
  • To execute this strategy, Rameda hired a new management team from leading multinationals with a proven track record to complement the existing team, and lead the transformation.

  • Rameda installed a state-of-the-art temperature control system in the warehouse facility.
  • A racking system was also added to the facility in order to increase pallet space in the warehouse, 3 from 900 pallets to 3,200 pallets.

  • German designer, M&W was commissioned to redesign the entire facility in order to upgrade to the latest design requirements of Good Manufacturing Practices (GMP) of the pharmaceutical industry

  • June 2011 saw the beginning of the implementation of the information technology upgrade, creation of the data warehouse facility, and the roll-out of computer systems to all employees.
  • Oracle was selected as the ERP software provider, and the physical implementation was launched.

  • The implementation of the water for injection production plant to produce sterile water for injectable plants was launched.
    The plant was commissioned for the leading Swiss provider, Romelag.

  • Plans to increase the capacity of the sterile cephalosporin injectable plant to increase the capacity from 23 units per year to 52 million units.
  • A cartoning machine from Marcasini was also added to the facility.

  • The non-sterile penicillin plant was redesigned to include tablets, and dry mix.
    A tablet press machine from IMA, the leading manufacturer in Italy, was acquired.

  • Seven dosage forms of branded generic products with a strong presence in the market were acquired.

  • Rameda created independent labs and a state-of-the-art warehouse facility for penicillin, and cephalosporin.

Products

Rametax

Form Rametax vial Composition Cefotaxime Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65